Compare AbCellera Biologics Inc (ABCL) vs Vanguard Total Bond Market Index Fund ETF (BND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Total Bond Market Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Vanguard Total Bond Market Index Fund ETF trades at $72.7. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | BND | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $75.17 |
52-Week Low | $2.78 | $72.45 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BND trades at $72.85, down 0.36% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at oversold levels. Recent dividend distributions of $0.24-$0.25 provide income appeal, while financial media highlights BND's role in diversified portfolios and compares it favorably against peers on yield and cost metrics.
The outlook remains cautious given the bearish technical setup and interest rate sensitivity. BND offers broad bond market exposure for income-focused investors, though duration risk persists if rates rise. Current levels may appeal to long-term investors seeking steady income with institutional quality diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →
